Eritoran (E5564), an MD2–TLR4 antagonist, was well tolerated in a Phase II sepsis trial (NCT00046072) and demonstrated trends toward lower mortality, suggesting translational potential in IPF (158). Here, TLR4 is linked to idiopathic pulmonary fibrosis.